Adjuvant Immunotherapy in Stage II Melanoma—Further Risk Stratification is Needed

Abstract

This Viewpoint reviews the evidence for immune checkpoint inhibitor use in the adjuvant setting, discusses the individual and societal risks, benefits, and costs associated with immune checkpoint inhibitors, and highlights the need for more targeted patient selection approaches.